Wednesday, July 8, 2026

biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases

Nanjing Legend Biotech

Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Ca

2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
Clinical program

anti-CD123 CAR-T treatment

Phase 1 · small molecule · Acute Leukemia

anti-CD123 CAR-T treatment for Acute Leukemia is a Phase 1 program (small_molecule) at Nanjing Legend Biotech Co. with 1 ClinicalTrials.gov record(s).

← All Nanjing Legend Biotech Co. projects Phase 1 small molecule terminated

Internal code anti-CD123 CAR-T therapy

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1
Modality
small_molecule
Indication
Acute Leukemia
Status
terminated
Trials
1